Does Xeljanz Increase Blood Clot Risk?
Yes, Xeljanz (tofacitinib) carries a boxed warning from the FDA for increased risk of blood clots, including deep vein thrombosis (DVT), pulmonary embolism (PE), and arterial thrombosis. This risk emerged from clinical trials and post-marketing data, particularly at higher doses (10 mg twice daily) or in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), or ulcerative colitis (UC). The label advises against use in patients with active serious infections or at high clot risk, and recommends the lowest effective dose.[1][2]
How Was This Risk Identified?
The warning stems from the ORAL Surveillance study, a large safety trial in RA patients over 50 with cardiovascular risk factors. It showed higher rates of major adverse cardiovascular events (MACE), including clots, with Xeljanz versus TNF inhibitors like Humira: 3.4% vs. 2.3% for venous thromboembolism (VTE). Risks rose with age, smoking history, and prior clots. FDA updated the label in 2021 based on this, restricting higher doses for RA and PsA.[1][3]
What Do Real-World Studies Show?
Post-approval data from registries and meta-analyses confirm elevated VTE risk. A 2023 analysis of over 100,000 RA patients found Xeljanz users had 1.5-2 times higher odds of DVT/PE compared to other biologics. Risks appear dose-dependent and higher early in treatment, though absolute rates remain low (around 0.5-1% per year).[4][5] No similar signal in younger UC patients at lower doses.
Who Faces the Highest Risk?
Patients over 50 with cardiovascular risks (e.g., smoking, hypertension, diabetes, prior clots) see the sharpest increases. Concomitant steroids or immobility amplify this. Label contraindicates use post-DVT/PE without alternatives. Monitor for leg swelling, chest pain, or shortness of breath.[1][2]
How Does Xeljanz Compare to Other JAK Inhibitors?
Similar warnings apply to Rinvoq (upadacitinib) and Olumiant (baricitinib) after shared trial data. Head-to-head, Xeljanz shows comparable VTE rates to Rinvoq (OR ~1.2 favoring neither), but all exceed TNF blockers. Abrocitinib (Cibinqo) for alopecia areata has a less prominent clot signal.[3][6]
What Precautions Do Doctors Recommend?
Start at 5 mg twice daily for RA/PsA; avoid 10 mg in high-risk groups. Screen for clot history pre-treatment. FDA mandates thrombosis risk discussion in patient medication guides. Discontinue if clots occur.[1][2]
Alternatives for High-Risk Patients
TNF inhibitors (e.g., Enbrel, Humira) or IL-17 blockers (e.g., Cosentyx) show lower clot signals in comparators. Methotrexate remains first-line for many. Biosimilars cut costs without added risks.[3][7]
Sources
[1]: FDA Xeljanz Label
[2]: FDA Boxed Warning Update
[3]: NEJM ORAL Surveillance
[4]: Arthritis Rheum VTE Meta-Analysis
[5]: JAMA Real-World RA Study
[6]: FDA Rinvoq Label
[7]: ACR RA Guidelines